Keyword: Aldeyra Therapeutics
Aldeyra Therapeutics aced a phase 3 trial of reproxalap for allergic conjunctivitis, sending its stock up at least 66% in premarket trading.
For $10 million upfront, Aldeyra is picking up a drug for proliferative vitreoretinopathy, which will enter the clinic in 2019.
The results tee Aldeyra up to move the aldehyde-binding small molecule into phase 3 next year.
Aldeyra Therapeutics and Janssen inked a pact to develop new drugs for inflammatory diseases.
Aldeyra says it has seen “statistically and clinically significant improvements” in a midstage trial for its experimental eye med ADX-102, although not all data points were positive.
A phase 2b trial of Aldeyra Therapeutics’ allergic conjunctivitis candidate ADX-102 has missed its primary endpoint.